Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862848 | 0.84 | KMT2A (0.49) | MEN1KMT2AL3MBTL1STSNPC1 | |
| SCHEMBL862849 | 0.83 | MEN1 (0.50) | MEN1KMT2AHRH3L3MBTL1NPC1 | |
| SCHEMBL863077 | 0.82 | MEN1 (0.52) | MEN1KMT2AHRH3L3MBTL1NPC1 | |
| SCHEMBL6210554 | 0.77 | MEN1 (0.51) | MEN1KMT2AHRH3L3MBTL1NPC1 | |
| SCHEMBL863094 | 0.77 | DHFR (0.39) | MEN1KMT2ANPC1HSD11B1 | |
| SCHEMBL5722254 | 0.76 | MEN1 (0.50) | MEN1KMT2AHRH3NPC1PDE4B | |
| SCHEMBL24041849 | 0.76 | MEN1 (0.43) | MEN1KMT2ANPC1 | |
| SCHEMBL9860211 | 0.75 | MEN1 (0.49) | MEN1KMT2AHRH3STSNPC1 | |
| SCHEMBL2281345 | 0.74 | SMN1; SMN2 (0.60) | MEN1KMT2AHRH3L3MBTL1NPC1 | |
| SCHEMBL1186911 | 0.74 | MEN1 (0.52) | MEN1KMT2ANPC1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143366-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2012-03-27 | — | — | US | disclosed |
| US-20100081782-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | EKWURIBE NNOCHIRI N | 2010-04-01 | — | — | US | disclosed |
| US-7625995-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2009-12-01 | — | — | US | disclosed |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-7335751-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | ALK, AOX1, OGFR | MEN1 4097/4885KMT2A 1543/4885HRH3 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.